Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinic ...
Right now, you can lock in help with PDFs forever with this lifetime subscription to PDF Converter and Editor, on sale for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback